The Effect of Subdural Drain Placement After Burr Hole Evacuation of Chronic Subdural Haematomas on Recurrence: a Prospective Randomised-controlled Multi-centre Study

February 6, 2013 updated by: Peter Woo Yat Ming, Kwong Wah Hospital

This is a prospective randomised-controlled multi-centre trial based in Hong Kong to determine whether temporary subdural drain placement after burr hole evacuation of a chronic subdural haematoma can reduce the risk of recurrence. Consecutive patients, 60 years old or above, diagnosed to have symptomatic chronic subdural haematoma and indicated for burr hole operative drainage will be randomly allocated into one of two groups: (1) for intra-operative subdural drain placement (intervention group) or (2) not for drain placement (control group). Using web-based software block randomisation with an allocation ratio of 1:1 will be conducted. Instructions to use or not to use a drain will be contained in a sealed envelopes labelled with sequential study numbers.

Intra-operatively, if the surgeon-in-charge judges that after burr hole evacuation of the haematoma the patient's condition is unsafe for drain placement, the subject will be excluded from the study. Otherwise, randomisation will be performed at this juncture by the opening of the sealed envelop. The procedure involves placing a prefabricated silicon drain into the subdural space according to a standard protocol and will be removed on the second post-operative day at the bedside. Subjects in whom the operating surgeon judges that drain placement is unsafe will be excluded from the study. Drainage is undertaken passively by hanging the collection bag at the bedside in a dependent position. In addition to general demographic, clinical and radiological presentation data, potential risk factors for recurrence will be documented. Serial computed tomography brain scans will be arranged (before discharge, at four weeks and six months) and the occurence of significant subdural haematoma recurrence requiring repeat operative drainage at six months will be recorded. Other outcome measures to be determined at regular time intervals for a total follow-up period of six months (upon discharge, at four weeks and six months) include: functional performance in terms of the extended Glasgow Outcome Scale and modified Rankin Scale, added neurological deficit, death and other surgery-related complications. All outcomes will be documented by the trial investigators or by the responsible clinician. The data obtained will be analysed according to the principle of intention to treat.

Hypothesis: compared to burr-hole evacuation of chronic subdural haematoma alone (control), the additional placement of a subdural drain after evacuation (intervention) will reduce the risk of recurrence requiring repeat surgery.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

260

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hong Kong
      • Hong Kong, Hong Kong, China
        • Prince of Wales Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Patients diagnosed to have symptomatic chronic subdural haematoma confirmed by a computed tomography or magnetic resonance imaging brain scan.
  2. Ethnic Chinese
  3. Age >/= 60 years-old
  4. Reasonable expectation of completion of outcome measures at follow-up
  5. Written informed consent

Exclusion Criteria:

  1. Unsalvageable patients: fixed and dilated pupils after resuscitation or signs of brainstem herniation that precludes definitive therapy.
  2. When the operating surgeon judges that drain placement may be hazardous or to be of limited benefit e.g. readily expanded brain in young patients.
  3. History of previous cranial neurosurgical procedure.
  4. On concurrent glucocorticoid therapy.
  5. Suspected intracranial hypotension syndrome.
  6. Blood dyscrasia:

    1. Use of antiplatelet medication e.g. aspirin or warfarin without adequate reversal or observation for drug effect to wear off (at least 5-7 days).
    2. Thrombocytopenia: platelet level <100 x 109/l
    3. Coagulopathy: prothrombin time PT >12sec or, activated partial thromboplastin time (APTT) >37.4 sec
  7. End-stage renal/ hepatic failure.
  8. Known or strong suspicion of alcohol or illicit drug abuse.
  9. Pregnancy
  10. Known epilepsy
  11. Any neurological or non-neurological condition independent from SAH that might influence the functional outcome or other efficacy outcome measures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
NO_INTERVENTION: Control: burr hole drainage only
Burr hole drainage of chronic subdural hematoma under general or local anesthesia without the subsequent placement of a subdural drain.
EXPERIMENTAL: Intervention: silicon subdural drain
Placement of a silicon subdural drain after burr hole drainage of a chronic subdural hematoma.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Significant recurrent chronic subdural hematoma i.e. requiring repeat operative drainage at six months after the primary operation
Time Frame: Six months after primary burr hole evacuation of chronic subdural hematoma
Six months after primary burr hole evacuation of chronic subdural hematoma

Secondary Outcome Measures

Outcome Measure
Time Frame
1. Functional performance in terms of the Extended Glasgow Outcome Scale
Time Frame: Upon discharge, 4 weeks and 6 months after primary operation
Upon discharge, 4 weeks and 6 months after primary operation
Added neurological deficit
Time Frame: Upon discharge, at 4 weeks and 6 months after primary operation
Upon discharge, at 4 weeks and 6 months after primary operation
Surgery-related complications
Time Frame: Upon discharge, at 4 weeks and 6 months after primary operation
Upon discharge, at 4 weeks and 6 months after primary operation
Death
Time Frame: Upon discharge, at 4 weeks and 6 months after primary operation
Upon discharge, at 4 weeks and 6 months after primary operation
Modified Rankin Score
Time Frame: Upon discharge, at 4 weeks and 6 months
Upon discharge, at 4 weeks and 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2013

Primary Completion (ANTICIPATED)

June 1, 2015

Study Completion (ANTICIPATED)

December 1, 2015

Study Registration Dates

First Submitted

February 5, 2013

First Submitted That Met QC Criteria

February 6, 2013

First Posted (ESTIMATE)

February 7, 2013

Study Record Updates

Last Update Posted (ESTIMATE)

February 7, 2013

Last Update Submitted That Met QC Criteria

February 6, 2013

Last Verified

February 1, 2013

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Subdural Hematoma

Clinical Trials on Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma

Subscribe